On the stock market since 2001, it operates in the world of health and science. It has 6,900 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 16% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 16% a year on average.
The company sells $3.2B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $207.9M against $3.2B in annual sales.
The stock trades 11% above the average analyst price target.
On our five-subject report card, EXAS sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: EXAS has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.